Crinetics Pharmaceuticals Inc. — Sponsor Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

5 Recruiting

5 Completed trials

14 Countries active

9 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase I (FiH)

Phase III: 4 Phase II/III: 1 Phase II: 4 Phase I (FiH): 1

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Acromegaly 3 Carcinoid syndrome 2

Top IMPs

PALTUSOTINE 5 ATUMELNANT 3 CRN04894 1 CRN09682 1

All trials

10 total

A Study in Pediatric Participants with Congenital Adrenal Hyperplasia Recruiting

2024-519578-38-00 Phase II/III 6 countries ATUMELNANT
A Study to Evaluate Atumelnant in Adults with Congenital Adrenal Hyperplasia Recruiting

2024-519579-24-00 Phase III 7 countries ATUMELNANT
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors Recruiting

2025-521672-60-00 Phase I (FiH) 4 countries CRN09682
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Recruiting

2024-519875-24-00 Phase III 8 countries PALTUSOTINE
A study to learn about the safety and effectiveness of CRN04894 on participants Recruiting

2024-514846-35-00 Phase II 2 countries ATUMELNANT
Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants with Congenital Adrenal Hyperplasia Ended

2023-503488-40-00 Phase II 2 countries CRN04894
Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome Ended

2024-511922-30-00 Phase II 1 country PALTUSOTINE
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study where subjects with non-pharmacologically treated acromeg… Ended

2024-511924-15-00 Phase III 7 countries PALTUSOTINE
Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Ended

2024-511925-71-00 Phase III 6 countries PALTUSOTINE
An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE) Ended

2024-511921-75-00 Phase II 3 countries PALTUSOTINE

Showing 1–10 of 10 trials

← All sponsors A–Z